


QUALITY **WORKS.**



LANXESS – Conference Presentation Q2 / 2017

The road ahead – expanding our strenghts

Investor Relations

LANXESS
Energizing Chemistry

Safe harbor statement

The information included in this presentation is being provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to purchase, securities of LANXESS AG. No public market exists for the securities of LANXESS AG in the United States.

This presentation contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.

Agenda

- **Expanding our strengths**
- Q2 2017 and guidance – Performing in the new LANXESS structure
- Backup

A rapidly changing world – Our answer: Energizing chemistry!

What it takes to be successful in a changing environment

Agility

Courage & team spirit

Mindset

Balance

Markets

Industries

LANXESS

Lean structures

Entrepreneurial organization

Speed


Leadership

Markets


Technology & innovation

A strong team and corporate culture make the difference

Our journey: Shaping New LANXESS – a story in three chapters



Recap Chapter 1: Rebuilding a competitive platform



Some value accretive portfolio modifications already addressed


Chapter 1 Repair

Chapter 2

Chapter 3

Strategic portfolio upgrade started

- Businesses already started to improve
- Businesses still up for improvement



Sound financials




EBITDA adj.: ~€255 m
 Synergies: ~€100 m
EV / EBITDA incl. synergies: ~7x



EBITDA adj.: ~€20 m
 Synergies: ~€10 m
EV / EBITDA incl. synergies: ~7x

Chemtura sales and EBITDA adjusted are based on FY 2016; USD / EUR 1.10

Restructuring and change of strategy yields first positive results



But it takes more time to change a company fundamentally

Chapter 1 Repair

Chapter 2

Chapter 3

- Industry balance and market set-up need further improvement
- Leadership positions in many business units achieved but substantial catch-up still to be done
- Margin and profitability level has visibly improved but still lagging behind industry standards



Chemtura integration: €100 m of synergies by 2020

Cost management


Organic investments

Portfolio management

Chapter 1

Chapter 2
Improve

Chapter 3



- Organizational streamlining
- Leveraging new regional strengths

€100 m synergy
breakdown:

Corporate /
country costs

~€30 m

Marketing and sales

~€20 m

Production and
procurement set-up

~€50 m

Topline synergies provide additional comfort

Organic investments will improve company ROCE

Cost management

Organic investments

Portfolio management

Chapter 1


Chapter 2
Improve

Chapter 3

- €100 m Debottleneckings, BU All
- €60 m Debottleneckings, BU SGO, custom manufacturing
- €60 m Greenfield, BU IPG
- €50-100 m Debottleneckings, BU HPM, global compounding hubs
- €50 m Debottleneckings in remaining BUs in Performance Chemicals
- €50-100 m Investments in Specialty Additives

**~€400 m capex until 2020 at
ROCE of ~20%**

% ROCE



Target: Increase ROCE to former levels

Portfolio optimizing with clear criteria

Cost management

Organic investments

Portfolio management

Chapter 1

Chapter 2
Improve

Chapter 3

Profitability

Resilience

**Acquisition /
divestment**

**Market and
technology
leadership**

Value creation

Chapter 3: More balanced and stronger platform along three key dimensions

Chapter 1

Regional platform



Industrial platform



Market positions



Chapter 2

Balancing the ground for further growth

- Regionally balanced platform with no pronounced dependencies
- Diversified industrial platform mitigates impact from any individual industry's volatility
- Market positions in every business at least among leading players to keep or improve profitability level



Chapter 3
Accelerate

Solid
growth

Chapter 3 will establish an even stronger platform

Vulnerability to single trends will be minimized


Chapter 1

Chapter 2


Chapter 3
Accelerate

Peak to trough EBITDA margin volatility not to exceed 2-3%pts

Illustrative: Margin volatility




- Former dependency on few cyclical businesses
- Lack of cushioning interference of cyclical swings



- Improved balance of portfolio, regions and industries
- Cyclicity scaled back


Use of entire toolbox to improve resilience

LANXESS free cash flow and cash conversion rate to improve



* Calculated as (EBITDA pre – capex) / EBITDA pre

Chapter 3: Ambitious financial goals – substantially higher margins with significantly lower volatility



Cash conversion: (EBITDA pre – capex) / EBITDA pre

The destination of our journey: A company with convincing characteristics

Business platform

- Nicely balanced: Regionally and industrially, thus less cyclical
- Leading market and technology positions

Financial profile

- Resilient cash conversion
- Investment grade rating

Cultural profile

- Enthusiasm for what we do
- Performance team culture as basis for the next steps after 2021



Agenda

- Expanding our strengths
- **Q2 2017 and guidance – Performing in the new LANXESS structure**
- Backup

Q2 2017 financial overview: a strong quarter in a dynamic environment

[€m]	Q2 2016	Q2 2017	yoy in %
Sales	1,943	2,522	30%
EBITDA pre	293	367	25%
margin	15.1%	14.6%	
EPS	0.82	0.04	-95%
EPS pre*	0.88	1.54	75%
Capex	73	105	44%
[€m]	31.12.2016	30.06.2017	Δ %
Net financial debt**	269	2,537	>100%
Net working capital	1,628	2,189	34%
ROCE***	6.9%	8.8%	

- Substantial sales increase driven by Chemtura and higher prices (raw material price pass-through)
- EBITDA pre reflects portfolio effects and positive price / raw material cost spread
- Net financial debt up due to ~€2.4 bn Chemtura acquisition
- Higher net working capital due to acquired businesses and substantially higher raw material prices

* net of exceptionals and amortization of intangible assets as well as attributable tax effects

** after deduction of current financial assets in 2016


*** 2017 calculated incl. Chemtura EBITpre pro forma based on 2016 earnings

Q2 2017: Strong results with nice contribution by Chemtura acquisition

Q2 yoy sales variances	Price	Volume	FX	Portfolio	Total
Advanced Intermediates	+5%	+1%	+1%	+7%	+14%
Specialty Additives	+1%	+4%	+1%	+101%	+107%
Performance Chemicals	+4%	-1%	+2%	+7%	+11%
Engineering Materials	+8%	+6%	+0%	+18%	+31%
ARLANXEO	+23%	-0%	+2%	+0%	+25%
LANXESS	+11%	+1%	+1%	+16%	+30%

- Sales increase reflects portfolio effect and successful raw material price pass-through
- Market demand remains healthy. Most BUs with positive volumes except for BU IPG (pricing), BU SGO (agro market) and BU TSR (maintenance turnaround)


Q2 yoy EBITDA pre bridge [€m]




- Successful raw material price pass-through
- “Other” includes contribution by Chemtura and Chemours’ clean & disinfect businesses

Q2 2017: Strong growth across all regions

Q2 2017 sales by region [%]



Regional development of sales [€ million]



* Currency and portfolio adjusted


Advanced Intermediates: Catch-up in raw material cost pass-through drives earnings

[€m]	Q2 2016	Q2 2017	Δ
Sales	443	505	14%
EBIT	63	65	3%
Depr./Amort.	25	29	16%
EBITDA pre exceptionals	88	97	10%
Margin	19.9%	19.2%	
Capex	22	33	50%

	H1 2016	H1 2017	Δ
Sales	906	1,023	13%
EBIT	127	130	2%
Depr./Amort.	50	55	10%
EBITDA pre exceptionals	177	188	6%
Margin	19.5%	18.4%	
Capex	31	49	58%



Q2 sales bridge yoy [€m]




Q2 yoy effects

- BU All with strong raw material-driven price increase and Chemtura Organometallics business contribution
- Volume growth in BU All held back by maintenance turnaround
- Weak agro chemical demand dampens BU SGO
- EBITDA benefits from catch up on raw material cost pass-through, partly mitigated by freight and energy costs


Specialty Additives: Results driven by portfolio effect

[€m]	Q2 2016	Q2 2017	Δ
Sales	213	440	>100%
EBIT	37	-8	<-100%
Depr./Amort.	8	32	>100%
EBITDA pre exceptionals	45	75	67%
Margin	21.1%	17.0%	
Capex	8	16	100%

	H1 2016	H1 2017	Δ
	434	679	56%
	72	29	-60%
	15	39	>100%
	87	119	37%
	20.0%	17.5%	
	13	23	77%



Q2 sales bridge yoy [€m]




Q2 yoy effects

- Major sales and earnings driver: Chemtura portfolio effect
- BU ADD with comparably stable price and volumes, BU RCH records strong volume growth
- EBITDA margin burdened by higher freight and energy costs, comparing to strong base


Performance Chemicals: Solid results

[€m]	Q2 2016	Q2 2017	Δ
Sales	330	367	11%
EBIT	54	-9	<-100%
Depr./Amort.	15	25	67%
EBITDA pre exceptionals	69	80	16%
Margin	20.9%	21.8%	
Capex	14	15	7%

H1 2016	H1 2017	Δ
642	735	14%
95	31	-67%
30	44	47%
125	139	11%
19.5%	18.9%	
25	26	4%



Q2 sales bridge yoy [€m]




Q2 yoy effects

- Higher prices in nearly all BUs
- Volume increases in BU MPP while BU IPG recorded lower volumes with higher prices
- EBITDA increase also reflects contribution of Chemours' Clean & Disinfect business


Engineering Materials: Strong volumes and better mix drive earnings

[€m]	Q2 2016	Q2 2017	Δ
Sales	275	361	31%
EBIT	34	45	32%
Depr./Amort.	11	15	36%
EBITDA pre exceptionals	45	72	60%
Margin	16.4%	19.9%	
Capex	4	11	>100%

	H1 2016	H1 2017	Δ
Sales	548	676	23%
EBIT	61	82	34%
Depr./Amort.	22	26	18%
EBITDA pre exceptionals	83	120	45%
Margin	15.1%	17.8%	
Capex	9	15	67%



Q2 sales bridge yoy [€m]



Q2 yoy effects

- Sales and EBITDA with portfolio effect from Chemtura Urethanes
- Strong demand across all regions drives volume growth in both BUs
- Prices up as higher raw material costs were passed on
- EBITDA improves on continued high capacity utilization, portfolio effect


ARLANXEO: Business continues to cope with challenging environment

[€m]	Q2 2016	Q2 2017	Δ
Sales	670	835	25%
EBIT	41	38	-7%
Depr./Amort.	54	57	6%
EBITDA pre exceptionals	95	92	-3%
Margin	14.2%	11.0%	
Capex	24	28	17%

	H1 2016	H1 2017	Δ
Sales	1,310	1,783	36%
EBIT	98	123	26%
Depr./Amort.	110	114	4%
EBITDA pre exceptionals	208	236	13%
Margin	15.9%	13.2%	
Capex	40	45	13%



Q2 sales bridge yoy [€m]



Q2 yoy effects

- Substantial price effect by raw material cost pass-through
- Continued good underlying demand in both BUs after exceptionally strong Q1. Some lower volumes in BU TSR due to planned turnaround
- EBITDA burdened by low double digit €- million inventory write off (mainly butadiene)
- Successful raw material cost pass-through offset mainly by higher energy costs

Q2 2017: Cash flow reflects first consolidation of acquired businesses

[€m]	Q2 2016	Q2 2017	
Profit before tax	147	61	<ul style="list-style-type: none"> Profit before tax declines due to substantial one-off restructuring and PPA (inventory step-up) Financial (gain) losses mainly contains reclassification of Currenta dividend to invest. CF Changes in other assets and liabilities includes provisioning for restructuring offset by variable compensation payout Working capital: PPA effect offsetting operational outflow
Depreciation & amortization	115	165	
Financial (gain) losses	16	-22	
Income taxes paid	-19	-28	
Changes in other assets and liabilities	-72	-42	
Operating cash flow before changes in WC	187	134	
Changes in working capital	-7	22	
Operating cash flow	180	156	
Investing cash flow	-981	289	
Thereof capex	-73	-105	
Financing cash flow	1,115	-69	

Operating CF below prior year due to transaction related cash-outs

Main balance sheet KPIs mirror acquisition

[€m]	Dec 2016	Jun 2017
Total assets	9,877	10,912
Equity (incl. Non-controlling interest)	3,728	3,579
Equity ratio	38%	33%
Net financial debt (after deduction of current financial assets)	269	2,537
Near cash, cash & cash equivalents	395	759
Pension provisions	1,249	1,416
ROCE¹	6.9%	8.8%
Net working capital	1,628	2,189
DSI (in days) ²	67	62
DSO (in days) ³	51	50

- Total assets increase due to Chemtura consolidation
- Equity ratio remains solidly above 30%
- Net financial debt increases due to payment for Chemtura, assumed debt and dividend payment
- Higher net working capital after M&A and substantially higher raw material prices
- Pension provisions mainly reflect Chemtura acquisition

¹ Based on last twelve months for EBIT pre, 2017 calculated incl. Chemtura EBIT pre pro forma based on 2016 earnings

² Days sales of inventory calculated from quarterly sales

³ Days of sales outstanding calculated from quarterly sales


FY 2017 on track – EBITDA guidance confirmed

Macro economics

- Persisting macroeconomic, geopolitical risks
- Agro chemicals demand modestly weaker than expected; while all other industries remain stable
- Asia Pacific continues to be the most attractively growing region

FY 2017

- Business dynamics solid, while growth expectations for H2 are softer due to the high comparable base in H2 2016
- **FY EBITDA pre between €1,225 m – €1,300 m**



FY 2017 EBITDA pre guidance includes contribution from the Chemtura acquisition as of April 21, 2017.

Inventory effects from PPA are treated as exceptional items

At USD/EUR 1.10

Agenda

- Expanding our strengths
- Q2 2017 and guidance – Performing in the new LANXESS structure
- **Backup**



Backup - Group

Housekeeping items

Additional financial expectations

- Capex 2017: ~€550-600 m (thereof ~€150 m ARLANXEO)
- Operational D&A 2017: ~€580-590 m (thereof ~€220 m ARLANXEO)
- Reconciliation 2017: ~-€190 m EBITDA pre incl. hedging
- Tax rate: Mid-term: 30-35% (for New LANXESS)



Please note:

- From Q2 2018 onwards, ARLANXEO will be shown as “discontinued operations”
- From Q2 2019 onwards, ARLANXEO will be accounted for “at equity”

At USD/EUR 1.10

ARLANXEO deconsolidation will lead to a substantial reduction of currency risk


Substantially reduced FX sensitivity

- Chemtura consolidated since 21 April 2017
- ARLANXEO reported as disc. operations from 01 April 2018

**1ct change in the USD/EUR rate impacts EBITDA
by ~€7 m before hedging
(was ~€9 m before)**



LANXESS has formed five strong segments



LANXESS Business Units

Former Chemtura Business Units

Phase II: progressing faster – ~€20 m savings pulled forward from 2017 to 2016

Detailed table to summarize financial impact of restructuring Phase II

	2015	2016	2017	2018	2019	Total
[€m] P&L expense (OTC)	~60	~30	~10			~100
[€m] Cash-out (OTC)	~5	~50	~20	~15		~90
[€m] Capital Invest	by 2019					~140
[€m] Cost reduction	~10	~20	~40	~40	~40	~150



Thereof ~€20 m
already realized
in 2016

Includes €20 m savings from the EPDM and Nd-PBR reconfiguration already communicated in March 2015 / OTCs include ~€55 m already communicated and booked in 2015 (Marl / Nd-PBR reconfiguration) / OTC = one-time-costs booked as exceptionals

Bottom-up analysis confirm former synergy targets

Implementation of synergies on track

[€m]	2017	2018	2019	2020	Total	
Synergies	~25	~25	~35	~15	~100	
Expense (one-time costs)*	~50	~50	~20	~20	~140	
Cash out*	~30	~40	~40	~30	~140	
Capex	~30	~10	~10		~50	


Previous assumptions

- **Synergies confirmed**
 - €100 m of “hard” costs
 - Top line synergies not included
- ~€50 m capex for asset improvements
- ~€140 m one time costs
- ~€80 m transaction related cash outs, mostly in 2017

* excluding ~€80 m transaction related charges

BU All: Brownfield expansion of existing manufacturing platform with highly attractive returns

Sensible debottleneckings to serve market growth



Total capex ~€100 m with Ø ROCE ~20%

Value investments


- Focus on brownfield investments
- Focus on continued technology upgrades and debottlenecking
- Further dilution of fixed costs
- Further improving excellent cost position

Support volume growth

Construction Ramp-up / production

BU HPM: Low capex intensity of downstream investments will further support the “balanced capacity model”

Expanding global compounding network inline with demand




Total capex €50 – 100 m with Ø ROCE ~20%

Construction Ramp-up / production

Value investments

Capacity split

Illustrative




Mix improvement

More stable and attractive returns

Actual utilization rates offer additional headroom




Increased profitability at stable utilization rates



- Rising share of EBITDA pre from New LANXESS businesses fueled margin improvement
- No indication of peak utilization rates
- Capex of the past allows to serve expected volume growth
- Growth capex adds to margin improvement

Potential for further increase in utilization rates and upside in financial performance


Growth capex in New LANXESS were value enhancing




* Sum of business units

H1 2017: Substantial growth across all regions

H1 2017 sales by region [%]




Regional development of sales [€ million]




* Currency and portfolio adjusted

Q2 2017: Strong operational and M&A driven increase in sales and EBITDA



Total group sales including reconciliation

H1 2017: Strong increase in Sales and EBITDA driven by acquisition of Chemtura



Total group sales including reconciliation

Q2 2017: Visible positive effect from Chemtura acquisition

[€m]	Q2 2016		Q2 2017		yoy in %
Sales	1,943	(100%)	2,522	(100%)	30%
Cost of sales	-1,466	(-75%)	-1,956	(-78%)	-33%
Selling	-191	(-10%)	-238	(-9%)	-25%
G&A	-73	(-4%)	-95	(-4%)	-30%
R&D	-32	(-2%)	-38	(-2%)	-19%
EBIT	176	(9%)	62	(2%)	-65%
Non-controlling interests	8	(0%)	11	(0%)	38%
Net Income	75	(4%)	3	(0%)	-96%
EPS pre*	0.88		1.54		75%
EBITDA	291	(15%)	227	(9%)	-22%
thereof exceptionals	-2	(0%)	-140	(-6%)	>100%
EBITDA pre exceptionals	293	(15%)	367	(15%)	25%

- Chemtura is major driver of deviations in all line items
- Sales increase on higher prices (raw material price pass-through) and portfolio
- Cost of sales also reflect higher raw material and energy costs
- Strong operational performance visible in EBITDA and EPS pre
- EBIT and Net Income affected by restructuring expenses and Chemtura related one offs (esp. PPA effect)

Substantial increase in EPS pre






* net of exceptionals and amortization of intangible assets as well as attributable tax effects

Balance sheet remains solid

[€m]	Dec 2016	Jun 2017		Dec 2016	Jun 2017
Non-current assets	4,519	6,558	Stockholders' equity	3,728	3,579
Intangible assets	494	1,813	attrib. to non-contr. interests	1,176	1,161
Property, plant & equipment	3,519	4,100	Non-current liabilities	4,516	5,020
Equity investments	0	0	Pension & post empl. provis.	1,249	1,416
Other investments	12	13	Other provisions	319	517
Other financial assets	19	20	Other financial liabilities	2,734	2,734
Deferred taxes	442	439	Tax liabilities	31	107
Other non-current assets	33	173	Other liabilities	93	116
			Deferred taxes	83	125
Current assets	5,358	4,354	Current liabilities	1,633	2,313
Inventories	1,429	1,733	Other provisions	406	474
Trade account receivables	1,088	1,389	Other financial liabilities	78	592
Other current financial assets	2,130	4	Trade accounts payable	889	933
Other current assets	316	469	Tax liabilities	44	73
Near cash assets	40	0	Other liabilities	216	241
Cash and cash equivalents	355	759			
Total assets	9,877	10,912	Total equity & liabilities	9,877	10,912

- Change in “Other current financial assets” reflects the acquisition of Chemtura

New LANXESS with strong ROCE

FY 2016	New LANXESS			ARLANXEO	Group
	 <p>Advanced Intermediates</p>	 <p>Performance Chemicals</p>			
EBITDA pre* margin	<p>€326 m 19%</p>	<p>€374 m 17%</p>	<p>€159m 15%</p>	<p>€373 m 14%</p>	<p>€995 m 13%</p>
ROCE	~15%			~5%	9.6%**


A solid EBITDA contribution from all segments

EBITDA pre and margin for HPM and ARLANXEO are unaudited figures; ROCE split is an approximation

* For segments: Operational EBITDA pre without allocation of hedging expenses

** Adjusted for current financial assets

Further potential for portfolio optimization



- First steps of portfolio optimization have been initiated in parts of LANXESS' portfolio
- Strategic directive for further portfolio optimization is already set

Ongoing implementation

* Reporting segment after acquisition of Chemtura

** ARLANXEO fully consolidated by LANXESS for the first three years (as of April 1, 2016)

■ Sales: > €500 m
 ■ Sales: €200 m – 500 m
 ■ Sales: < €200 m

Corporate Responsibility well integrated - achieving goals sustainably

Climate / Environmental goals

- Reduction of specific CO₂ emission by 25%¹ until 2025
- Reduction of specific energy consumptions by 25%¹ until 2025
- Reduction of volatile organic compounds (NMVOC³) emissions by 25%¹ until 2025

Procurement initiatives

- 'Supplier Code of Conduct' for supplier selection and rating
- 'Together for Sustainability' initiative² for higher transparency in the supply chain (implementation of a global auditing program)

Safety goals

- Xact: Global safety program to improve occupational, process and plant safety (since 2011)
- Global management system for optimization of transportation of (dangerous) goods

Social initiatives and goals

- Global board initiative 'Diversity & Inclusion': raising the proportion of women in management to 20% by 2020
- Leverage water know-how: support of AMREF⁴
- Education initiatives with local and global commitment




¹ Base year: 2015; for CO₂: Scope 1 and Scope 2 emissions

² Members: BASF, Bayer, Evonik, Henkel, LANXESS, Akzo Nobel, Solvay

³ Non methane volatile organic compounds; ⁴ African Medical and Research Foundation

A word on pensions: Mind the assets

Pension provision less deferred tax asset [€m]



At 4% discount rate gross pension provision declines to €1.0bn

Pension Provision €1,416 m  applicable tax rate

Tax asset of €272 m and plan asset of €60 m*
~€3.60 / share

Pension provision net of tax and plan assets
€1,085 m


*as per 30 June 2017

Maturity profile actively managed and well balanced

Long-term financing secured

- Liquidity position normalized with closing of Chemtura acquisition on 21st April 2017
- Diversified financing sources
 - Bonds & private placements
 - Syndicated credit facility
- Chemtura Bond early redeemed on 15th July 2017
- Average interest rate of financial liabilities <3%
- All group financing executed without financial covenants

Liquidity and maturity profile as per June 2017




* Hybrid bond with contractual maturity date in 2076 has a first optional call date in 2023

** Restricted assets held for early redemption of Chemtura Bond on 15th July 2017

High volatility in raw material prices

Global raw materials index



- Sharp decline in raw material prices in Q4 2014/ Q1 2015 driven by a steep drop in the price of oil
- 2015: Volatile raw material prices trended downwards through year end
- 2016 with an upward trend that accelerated during Q4
- 2017 started with a spike in raw material prices which we expect to largely reverse in H2 2017

LANXESS excluding Chemtura businesses, average 2013 = 100%,

Overview exceptional items H1 2017

[€m]	Q2 2016		Q2 2017		H1 2016		H1 2017	
	Excep.	Thereof D&A	Excep.	Thereof D&A	Excep.	Thereof D&A	Excep.	Thereof D&A
Advanced Intermediates	0	0	3	0	0	0	3	0
Specialty Additives	0	0	57	6	0	0	57	6
Performance Chemicals	0	0	70	6	0	0	70	6
Engineering Materials	0	0	13	1	0	0	13	1
ARLANXEO	0	0	-3	0	0	0	-1	0
Reconciliation	2	0	13	0	13	0	23	0
Total	2	0	153	13	13	0	165	13

Abbreviations

Advanced Intermediates

- All Advanced Industrial Intermediates
- SGO Saltigo

Performance Chemicals

- IPG Inorganic Pigments
- LEA Leather
- MPP Material Protection Products
- LPT Liquid Purification Technologies

Specialty Additives

- ADD Additives*
- RCH Rhein Chemie

Engineering Materials

- HPM High Performance Materials
- URE Urethane Systems

ARLANXEO*

- TSR Tire & Specialty Rubbers
- HPE High Performance Elastomers

* ARLANXEO to be fully consolidated for the first three years (as of April 1, 2016)




Backup – Specialty Additives / Chemtura


Specialty Additives benefits from attractive growth dynamics driven by customer needs



Customers require more specialized and efficient solutions



Solid growth perspective



- Megatrends Urbanization and Mobility
- Increasing demand for plastics and polymers
- Solid growth in core markets



* LANXESS Segment Specialty Additives core applications (E&E, Transportation, Construction, General Industries) / Source: World Industry Service & LANXESS Research

Segment Specialty Additives: A leading player based on a unique business set-up



Resilient by nature

Sales FY 2016 pro forma



Strongly positioned

- Comprehensive product portfolio and global network
- Fully fledged asset platform with high technical standard
- Strong value chain integration
- Market dynamics and synergies leverage stable growth



BU Additives leading market player with strong backward integration



Among the top global players

Market shares*:

Brominated flame retardants:
1/2 in in Europe
2 globally




Phosphorous flame retardants:
2 in Europe
3/4 globally



Strong value chains

Illustrative

Fully integrated bromine value chain:



Unique lubricants value chain:



Stronghold characteristics

- Leading market positions
- Global sales and distribution network
- Multiple strong value chains
- Solution provider driving innovations


* Source: European Commission, IHS Specialty Chemicals Update Program – Flame Retardants 2014

Lubricant Additives benefits from fully integrated value chain




Most attractive value chain for customers


Illustrative



LANXESS



Lubricant Additives sales split:



- Additives
- Base stocks
- Intermediates
- Others

Synergies leverage growth


- Unique integrated value chain offers attractive cross selling opportunities
- Broad product portfolio with high technical expertise
- Growth above GDP driven by advancing technical applications

Flame retardants with complementary and most attractive business set-up




Clear strategic focus

Global consumption of flame retardants by type*



Emphasis on growth markets

LANXESS' end markets for phosphorous and brominated flame retardants



Sales FY 2016 pro forma

Promising growth drivers

- Highest potential for product specialization and differentiation
- Rising demand for PU, TPU, PS and PVC*** within end markets
- Increasing CO₂ efficiency requirements
- Tightened regulatory and safety standards

* Source: IHS Specialty Chemicals Update Program – Flame Retardants 2014, SCI Study Flame Retardants China 2016, LANXESS Research


** ATH = Aluminium-tri-hydrochloride; *** Polyurethane, thermoplastic polyurethanes, polystyrene and polyvinyl chloride

Flame retardants benefit from trend towards more sophisticated solutions for fire protection



LANXESS drives innovation & technology

Striking characteristics




- Broad and advanced product portfolio based on high technical expertise
- The only bromine player with strategic focus on bromine solutions
- Strategic focus on product development to meet market expectations

Bromine Excursus: An integrated leading bromine player with a strong and diverse bromine portfolio



Strong backward integration

Among top three players



- Natural oligopolistic market structure with 75% dominated by three players
- Cost competitive bromine extraction
- Leading transportation fleet for elemental bromine
- Bromine reserves last more than 75 years

LANXESS bromine production is located in El Dorado, Arkansas, USA

* ICL, Albemarle and LANXESS

BU Additives will leverage its position as global additives player



Integrate

- Business integration and implementation of synergies
- Leverage improved regional footprint using enlarged sales and distribution network

Enhance

- Realize cross-selling opportunities and increase competitiveness
- Extend business focus on Asia Pacific

Develop

- Strategic focus on product development
- Specialize and innovate our product portfolio



Chemtura impact: Financial indications

Chemtura 2016 – US GAAP based

▪ Sales:	\$1,654 m	[~€1,504 m]
▪ EBITDA adj.*	\$282 m	[~€256 m]
▪ Capex 2016:	\$88 m	[~€80 m]
▪ D&A 2016:	\$85 m	[~€77 m]
▪ Net financial debt	\$256 m	[~€233 m]

2017

- EBITDA contribution for 2/3 of the year
- Detailed financial information for 2017 to follow with Q2 2017 reporting
- Detailed bottom-up analysis has started

First indicative considerations after closing

- Inventory step-up: ~-€60 m, mainly in Q2 2017 (treated as exceptional)
- Additional impact on D&A due to purchase price allocation:
 - 2017: ~€40 m
 - 2018ff p.a.: ~€60 m

All Euro figures translated at USD/EUR 1.10

* Excluding Chemtura's agro business

Acquisition of Chemtura: Establishing a major global additives player



**A global, specialty chemical company
operating in the attractive field of additives**

Lubricant additives



Flame retardants



- Sales ~€1.5 bn
- EBITDA adj. ~€245 m
- ~2,500 employees
- 20 sites in 11 countries

Rationale of acquisition:

- Complementary additive businesses with significant synergies (~€100 m)
- Strengthening global presence and end market diversification
- Strengthening business risk profile

- Equity value ~€1.9 bn (\$33.50 per share)
- Net financial debt and pensions ~€500 m
→ Enterprise value of ~€2.4 bn

**EV/EBITDA ~7x
including synergies**

- Closing April 2017


Sales and EBITDA are based on Q2 2016 LTM, USD/EUR 1.10

Chemtura has a growing and profitable additives business with a strong US footprint



A global, specialty chemical company*


- Sales ~€1.5 bn
- EBITDA pre ~€245 m
- ~2,500 employees
- 20 sites in 11 countries



■ North America ■ Europe
■ Asia ■ Latin America

Well established in lubricant additives and flame retardants

Sales split



Key customer bases growing**

Building & construction



~3.0%

Electrical & Electronics



~5.5%

Energy



~2.0%

Transportation



~3.5%

Sales and EBITDA are based on Q2 2016 LTM, USD/EUR 1.10

* Listed at NYSE, Headquarters: Philadelphia, PA (US)

**CAGR: 2016-2020 (based on IHS)



Backup - ARLANXEO

Reporting treatment of ARLANXEO with significant impact on LANXESS' financial shape



5 year lock-up period negotiated between Saudi Aramco and LANXESS

3 years casting vote at LANXESS



ARLANXEO effects on LANXESS' income statement, P&L and cash flow

Discontinued operations from Q2 2018

P&L:

- P&L down to after tax income will stop reflecting ARLANXEO
- 100% of ARLANXEO net income* will be shown as “income from discontinued operations”
- 50% of ARLANXEO net income is then attributable to “non-controlling interest”

Balance sheet:

- ARLANXEO assets will be bundled in one position “assets -” and “liabilities from discontinued operations”

Cash Flow:

- Operating / investing / financing cash flow will each be split in “continuing” and “discontinued” portion either in the statement or in the notes

At equity consolidation from Q2 2019

P&L:

- LANXESS will account for its 50% ARLANXEO stake at equity

Balance sheet:

- ARLANXEO's assets & liabilities and Aramco's equity share leave LANXESS' balance sheet
- 50% of ARLANXEO stake will be reflected in “investments accounted for using the equity method”

Cash Flow:


- In case dividends are paid from ARLANXEO to both parents, this will be shown in investing cash flow

 * IFRS 5: Non-current assets shall not be depreciated/amortized when shown as discontinued operations

ARLANXEO with marginal contribution to EPS – New LANXESS tax rate reduced after deconsolidation


Minor ARLANXEO contribution to EPS

H2 2017 LTM



High ARLANXEO D&A after heavy investment cycle


Tax rate of New LANXESS will be at 30-35%



High ARLANXEO tax rate due to unfavorable regional distribution of earnings

Volatility of working capital will be significantly reduced after deconsolidation of ARLANXEO

ARLANXEO significantly impacted free cash flow in the past



- Butadiene, one of the main raw materials for ARLANXEO, with strong volatility
- Butadiene volatility main driver for working capital changes in the past

Volatility of working capital will be significantly reduced

Upcoming events 2017/2018

Proactive capital market communication

- | | | |
|--|--------------------|----------------|
| ▪ SdK Börsentag Hannover | September 13 | Hanover |
| ▪ 6th Annual Goldman Sachs & Berenberg German Corp. Conference | September 18/19 | Munich |
| ▪ Baader Investment Conference 2017 | September 18/19 | Munich |
| ▪ Q3 2017 results | November 15 | |
| ▪ Deutsches Eigenkapitalforum 2017 | November 28 | Frankfurt |
| ▪ Berenberg European Corporate Conference | December 4 | Pennyhill |
| ▪ FY 2017 results | March 15 | |
| ▪ Q1 2018 results | May 9 | |
| ▪ Annual General Meeting 2018 | May 15 | Cologne |
| ▪ Q2 2018 results | August 1 | |
| ▪ Q3 2018 results | November 8 | |

Contact details Investor Relations

Oliver Stratmann

Head of Treasury & Investor Relations

Tel. : +49-221 8885 9611
Fax. : +49-221 8885 5400
Mobile : +49-175 30 49611
Email : Oliver.Stratmann@lanxess.com



Annika Klaus

Assistant to Oliver Stratmann

Tel. : +49-221 8885 9834
Fax. : +49-221 8885 4944
Mobile : +49-151 74613059
Email : Annika.Klaus@lanxess.com



LANXESS IR website



Ulrike Rockel

Head of Investor Relations

Tel. : +49-221 8885 5458
Mobile : +49-175 30 50458
Email : Ulrike.Rockel@lanxess.com



Katharina Forster

Institutional Investors / Analysts / AGM

Tel. : +49-221 8885 1035
Mobile : +49-151 7461 2789
Email : Katharina.Forster@lanxess.com



Jens Ussler

Institutional Investors / Analysts

Tel. : +49-221 8885 7344
Mobile : +49-151 7461 2913
Email : Jens.Ussler@lanxess.com



Thorsten Zimmermann

Institutional Investors / Analysts

Tel. : +49-221 8885 5249
Mobile : +49-151 7461 2969
Email : Thorsten.Zimmermann@lanxess.com

